Innovus Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference in New York

SAN DIEGO, Feb. 5, 2014 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company"),, (OTCBB:INNV) today announced that Dr. Bassam Damaj, Ph.D., Chief Executive Officer and President, will present at the 16th Annual BIO CEO & Investor Conference, to be held at the Waldorf-Astoria Hotel in New York February 10-11, 2014. Dr. Damaj is scheduled to present on Monday, February 10th at 11:00 a.m. EST in the Conrad Room. Dr. Damaj will give an overview of the Company and discuss the recent acquisition of Semprae Laboratories, Inc., the Company's growing pipeline and its projected growth. In addition, he will preview the recent accomplishments of the Company and the upcoming milestones.

About Innovus Pharma

Innovus Pharma, headquartered in San Diego, California, is an emerging leader in the OTC male and female sexual dysfunction products. The Company sells Zestra® for female arousal, Zestra® Glide as complimentary water based lubricant, EjectDelay™ for premature ejaculation and CIRCUMSerum™ to alleviate reduced penile sensitivity ex-US.

For more information, go to

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may be considered to be "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that may individually or mutually impact the matters described in this release for a variety of reasons, many of which are outside the control of Innovus Pharma. These risks and uncertainties include, but are not limited to Innovus Pharma's ability to raise sufficient capital to fund its operations and growth strategy, the continued willingness of members of the Board of Directors to fund the company on an interim basis, Innovus Pharma's ability to achieve its development, regulatory, commercialization and financial goals for its existing products, its ability to fully integrate its Semprae Laboratories, Inc., subsidiary, its ability to acquire additional products, and its ability to achieve development, regulatory, commercialization and financial goals for such additional products. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or the "Investors" section of Innovus Pharma's website at

CONTACT: Kevin Holmes Chesapeake Group T: 410-825-3930Source:Innovus Pharmaceuticals, Inc.